AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

20.11 0.66 +3.39%
Market cap
$6.8B
P/E
38.2×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
7 5 5 4 6 7 3 — — 3
P/E ratio
54.78 0.00 0.00 0.00 69.22 8.61 0.00 0.00 0.00 0.00
Altman Z-Score
1.94 1.35 1.06 0.61 0.94 0.84 0.41 0.86 — —
P/S ratio
1.31 0.88 0.44 0.14 0.34 0.34 0.39 1.04 0.96 0.96
P/FCF ratio
17.34 11.12 3.81 6.76 1.61 2.15 0.00 9.65 11.38 11.38
Altman Z″-Score (non-manufacturers)
2.06 0.74 0.95 0.67 1.54 1.45 0.50 1.33 2.39 2.89
P/Operating CF
30.30 20.72 7.75 (13.67) 11.28 6.36 (12.51) 6.63 39.76 39.76
Beneish M-Score
(2.68) (2.83) (3.18) (2.76) (2.79) (2.95) (2.67) 0.89 (2.88) (2.49)
P/B ratio
0.00 0.00 52.64 1.73 1.94 1.95 1.84 1.92 18.03 18.03
EV/Sales
2.06 1.74 1.50 1.36 1.53 1.61 1.95 2.52 1.56 1.56
EV/EBITDA
9.70 9.47 8.07 19.53 8.11 9.55 2,229.97 31.30 4.39 4.39
EV/FCF
27.27 22.13 13.01 63.75 7.21 10.24 (33.18) 23.50 18.63 18.63
Current Ratio
2.17 1.41 1.63 1.88 2.24 2.29 2.20 2.32 2.60 1.96
Net Debt/EBITDA
3.62 4.71 5.71 17.46 6.30 7.54 1,783.00 18.45 4.76 2.03
Debt/Equity
(36.83) (23.22) 131.96 14.79 7.49 8.34 7.76 3.00 (3.95) 1.33
ROE
(79.69%) 261.19% (82.35%) (47.19%) 2.98% 26.33% (58.23%) (8.03%) 0.00% 0.00%
ROA
2.01% (3.35%) (2.31%) (3.36%) 0.27% 2.37% (9.03%) (0.73%) 0.00% 0.00%
ROIC
10.97% 6.73% 4.99% (2.07%) 3.34% 1.98% (5.39%) (0.36%) 14.86% 13.96%
Return on Tangible Assets
4.89% (13.24%) (8.58%) (11.52%) 0.78% 6.73% (31.81%) (1.64%) 0.00% 0.00%
Average Days of Receivables
108.29 101.40 93.73 122.47 115.72 117.29 136.04 105.86 129.80 93.52
Earnings Yield
1.83% (4.80%) (7.95%) (40.76%) 1.44% 11.61% (57.26%) (45.58%) (43.44%) (43.44%)
Free Cash Flow Yield
5.77% 8.99% 26.24% 14.80% 62.30% 46.42% (15.03%) 10.37% 8.79% 8.79%
Free Cash Flow per Share
0.73 0.71 1.57 (0.17) 1.30 2.12 (0.72) 1.40 1.62 (0.13)
Book value per Share
(0.23) (0.35) 0.11 1.22 2.46 2.34 2.63 7.04 (5.08) 8.79
Free Cash Flow
227.73 220.11 276.39 (25.49) 194.18 312.82 (95.73) 178.49 119.92 (9.55)
EV/EBIT
15.76 19.54 17.59 0.00 20.99 35.14 0.00 0.00 4.88 4.88
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026